LEADER: Evaluation of Ventricular Pacing Suppression Algorithms in Dual Chamber Pacemaker

Sponsor
Keimyung University Dongsan Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03843242
Collaborator
Biotronik SE & Co. KG (Industry)
146
6
3
54.1
24.3
0.4

Study Details

Study Description

Brief Summary

The recent study using IRSplus and VpS algorithm from Biotronik pacemaker showed the significant reduction in ventricular pacing to less than 3%.

The purpose of this study is to evaluate the efficacy of IRSplus and VpS algorithm in reducing ventricular pacing compared with conventional DDD pacing with a fixed AV delay.

Condition or Disease Intervention/Treatment Phase
  • Device: Pacemaker with Fixed long AV delay
  • Device: Pacemaker with VpS® algorithm on
  • Device: Pacemaker with IRSplus algorithm on
N/A

Detailed Description

The adverse cardiac outcomes due to right ventricular apical pacing with dual chamber pacemakers have been widely observed such as ventricular dyssynchrony resulting in reduced left ventricular function, increased risk of heart failure and atrial fibrillation. To minimize the ventricular pacing, manufacturers of pacemaker have made an effort to develop special algorithms designed to deliver right ventricular pacing only in case of demonstrated persistent long PR interval or repetitively lacking intrinsic ventricular activation.

Currently, there are three methods and algorithms are available with a pacemaker from the Biotronik SE & Co. KG to minimize right ventricular pacing as follows; DDD mode with fixed longer atrioventricular (AV) delay than intrinsic conduction time; Intrinsic rhythm support (IRSplus); Ventricular pacing suppression (VpS).

In the real world, it is the most common practice to program the DDD(R) mode with fixed long AV delay because of physician's concerns about the possible failure of an algorithm or long pause being resulted from 2 consecutive loss of AV conduction by the algorithm. However, the main disadvantage of a fixed with long AV delay is that the prolonged total atrial refractory period (TARP) results in changes of the upper rate behavior (i.e., pseudo-Wenckebach AV block and subsequently 2:1 block at lower atrial tracking rates). The possibility of pacemaker-mediated tachycardia is getting high if the post-ventricular atrial refractory period (PVARP) is shortened to compensate. Furthermore, there is a high chance to have fusion/pseudo-fusion of ventricular pacing in a fixed long AV delay because the AV conduction is dynamic according to the heart rate.

The recent systematic review showed that there are no significant differences between the pacing modes for mortality, heart failure, stroke, and atrial fibrillation (AF) in patients with sinus node dysfunction (SND) without AV block. However, the dual chamber pacemaker is still recommended in patients with SND due to lack of tools to identify patients at high risk of developing the complete AV block. The meta-analysis about the effect of the reduction in unnecessary ventricular pacing using a sophisticated algorithm in patients with SND showed there are no benefits in clinical outcomes compared with conventional DDD mode. But the percentage of ventricular pacing in ventricular pacing reduction modality group was not negligible between 1~11.5%. The result might be changed if we have data with a more significant reduction in ventricular pacing using difference algorithm. The recent study using IRSplus and VpS algorithm from Biotronik pacemaker showed the significant reduction in ventricular pacing to less than 3%.

The purpose of this study is to evaluate the efficacy of IRSplus and VpS algorithm compared with conventional DDD pacing with a fixed AV delay.

Study Design

Study Type:
Interventional
Actual Enrollment :
146 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Ventricular Pacing Suppression Algorithms in Dual Chamber
Actual Study Start Date :
May 30, 2019
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pacemaker with Fixed long AV delay

Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible. The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months. Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec

Device: Pacemaker with Fixed long AV delay
Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.

Experimental: Pacemaker with VpS® algorithm on

Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.

Device: Pacemaker with Fixed long AV delay
Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.

Device: Pacemaker with VpS® algorithm on
After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm.

Experimental: Pacemaker with IRSplus algorithm on

IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.

Device: Pacemaker with Fixed long AV delay
Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.

Device: Pacemaker with IRSplus algorithm on
After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm.

Outcome Measures

Primary Outcome Measures

  1. Percentage of right ventricular pacing [During first 3 months after the study enrollment]

    the right ventricle pacing percentage appeared on the pacemaker interrogation

  2. Percentage of right ventricular pacing [During 4 ~ 9 months after the study enrollment]

    the right ventricle pacing percentage appeared on the pacemaker interrogation

  3. Percentage of right ventricular pacing [During 10 ~ 15 months after the study enrollment]

    the right ventricle pacing percentage appeared on the pacemaker interrogation

Secondary Outcome Measures

  1. New onset atrial fibrillation [During 12 months after randomization (15 months after enrollment)]

    Percentage of patients with new onset atrial fibrillation during the observation period

  2. Occurrence of heart failure [During 12 months after randomization (15 months after enrollment)]

    Percentage of patients who experienced symptomatic heart failure during the observation period

  3. Percentage of atrial high rate episode [During 12 months after randomization (15 months after enrollment)]

    Percentage of atrial high rate episode appeared on the pacemaker interrogation

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Sick sinus syndrome

  • No evidence of 2nd and 3rd degree AV block

  • Provide written informed consent

  • Age ≥ 20 years old

Exclusion Criteria:
  • 2nd and 3rd degree AV block

  • History of AF

  • patients with older version of pacemaker

  • Life expectancy ≤ one year

  • Pregnant or lactating women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Daegu Fatima Hospital Daegu Korea, Republic of 41199
2 Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital Daegu Korea, Republic of 41944
3 Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital Daegu Korea, Republic of 42415
4 Division of Cardiology, Department of Internal Medicine, Daegu Catholic University Medical Center Daegu Korea, Republic of 42472
5 Dongguk University Medical Center Ilsan Korea, Republic of
6 Pusan National University Hospital Pusan Korea, Republic of 49241

Sponsors and Collaborators

  • Keimyung University Dongsan Medical Center
  • Biotronik SE & Co. KG

Investigators

  • Study Chair: Seongwook Han, M.D., Ph.D., Keimyung University Dongsan Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Seongwook Han, Professor of Internal Medicine, Keimyung University Dongsan Medical Center
ClinicalTrials.gov Identifier:
NCT03843242
Other Study ID Numbers:
  • 2018-08-022
First Posted:
Feb 18, 2019
Last Update Posted:
Mar 15, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2022